Corporate | 12 September 2016 11:30


Evonik Industries AG: Evonik reduces production capacity for superabsorbents

DGAP-News: Evonik Industries AG / Key word(s): Miscellaneous

2016-09-12 / 11:30
The issuer is solely responsible for the content of this announcement.

Evonik reduces production capacity for superabsorbents

Essen. Evonik recently reduced production capacity for superabsorbents by 40,000 metric tons to 530,000 meric tons per year. The production lines concerned are those at the Garyville and Greensboro (North Carolina, USA) sites, two of Evonik’s five superabsorbents production sites worldwide.

“With this measure we’re adapting to demand trends. We plan to take the opportunity to bring capacity to the technological state of the art and to start up the lines again in 1 – 2 years,” says Norbert Westerholt, head of the Baby Care Business Line at Evonik.

Evonik is pursuing the goal of remaining a reliable, competitive, and innovative partner of superabsorbents customers over the long term.

As one of the leading suppliers of superabsorbents, Evonik is established as a reliable, innovative and long-term partner in the superabsorbents industry.





Company information
Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Profitable growth and a sustained increase in the value of the company form the heart of Evonik’s corporate strategy. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2015 more than 33,500 employees generated sales of around EUR13.5 billion and an operating profit (adjusted EBITDA) of about EUR2.47 billion.

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,000 employees, and generated sales of around EUR4.9 billion in 2015

Disclaimer
In so far as forecasts or expectations are expressed in this Investor Relations News or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.





Contact:
Tim Lange
Head of Investor Relations
Phone +49 201 177-3150
tim.lange@evonik.com
Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone +49 201 177-01
Telefax +49 201 177-3475
www.evonik.com

Supervisory Board
Dr. Werner Müller, Chairman
Executive Board
Dr. Klaus Engel, Chairman
Christian Kullmann, Deputy Chairman
Dr. Ralph Sven Kaufmann
Thomas Wessel
Ute Wolf

Registered office Essen
Registered court
Essen local court
Commercial registry B 19474
VAT ID no. DE 811160003

2016-09-12 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Germany
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: investor-relations@evonik.com
Internet: www.evonik.com
ISIN: DE000EVNK013, XS0911405784
WKN: EVNK01, A1TM7T
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxemburg
End of News DGAP News Service

show this